Emerging markets mobile minnow Synchronica is seeing momentum build behind its low-cost Blackberry-like phone, the ‘MessagePhone’.
Although historically a software specialist, the company has, in partnership with a large but unnamed global player, produced a new low-cost mobile device that looks and works like a Blackberry phone but is specifically for users in emerging markets. A recent order for 20,000 MessagePhones from a South American subsidiary of 'one of the largest worldwide operators', follows a maiden deal in November from another operator in Africa.
Synchronica’s co-founder and CEO Carsten Brinkschulte says ‘the order from such a dominant operator in the telecommunications market and in Latin America shows the traction of Synchronica's product in regions where PC ownership is low and where operators can offer email and mobile synchronisation direct to customers on a low cost device’. Synchronica will receive 3% of the net revenue from the sales of the phones as well as the various revenues from its Mobile Gateway software.
Mobile Gateway enables mobile users with basic phones to access their emails and is therefore sold to mobile networks focused on developing markets, a sales opportunity that represents over two-thirds of global mobile subscriptions. The Tunbridge Wells-based company has sold into Scandinavia, Eastern Europe, Africa, Asia and South America, accumulating numerous pilot scheme licences that are expected to roll out into full contracts.
Synchronica's recent trading update confirmed that 13 mobile operators had signed up to Mobile Gateway last year, after eight new contracts were added in the second half. However, ‘final documentation’ for a significant order is still needed before the company can reach the market's £4.5m sales forecasts, with losses slashed by more than half to just over £1m.
Shares in Synchronica, floated at 130p in 2004, have fluctuated between 2.6p and 4.6p in 2009 and should move higher once break-even is achieved this year.
Market cap: £17.32m
PE Forecast: n/a
Share price: 3p
More breaking news stories.
More extended feature articles.
And a depth of analysis you
can't find anywhere else.
Advertisement
VCT Report 2010 uncovers the money available
for investment in every single VCT, helping you get one step ahead in the race to attract funding for your unquoted, AIM-listed or PLUS-quoted
company.
Order VCT Report 2010 today using this online form
A comprehensive overview of cash shells on AIM and PLUS, companies that have become a significant feature on the market landscape. For more information and to order, click here or contact our marketing team on 020 7250 7056.
Informative features and research on fast-growing companies, small-cap and growth stocks, penny shares, stock market tips and share recommendations, directors' dealings, company news and analysis, new issues and upcoming IPOs.
A full year's subscription to What Investment magazine for £19.95, a whopping 58% off. Get the latest news, features and expert advice on ISAs, Investment Trusts and Funds, SIPPS, Investing for Children and much much
more. Find out more here.
is the definitive and most up-to-date guide to completing your self-assessment tax return, making sure that you get it right and on time, and showing how you can save tax. For more information and to order, click here or contact our marketing team on 020 7250 7056.
The new, fully updated AIM Guide is now available to buy for only £49.95 (saving you £30).
A 'must-have' for any serious investor or professional interested in the market for young, fast-growing companies. Order your copy today Hurry, as offer ends soon!
Small-cap and growth company share recommendations on AIM- and PLUS-listed companies. Latest analysts' stock tips and advice on which are the best shares to buy on London's junior stock markets.
Advertisement
Delcam, the international seller of CAD/CAM software to the engineering, aerospace and healthcare sectors among others, is a cash-generative small-cap seeing recovery in its markets.
Bombed-out biotech play Antisoma is hoping two of its drugs will lead to good fortune after experiencing disaster with lung cancer treatment ASA404.
GW Pharmaceuticals has won approval from Health Canada for its cannabis-based Sativex product to treat spasticity caused by Multiple Sclerosis.